Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia

Journal of Nuclear Medicine

Volumn 47, Issue 8, 2006, Pages 1335-1341

  Glatting, Gerhard ^a   Müller, Marguerite ^a   Koop, Bernd ^a   Hohl, Kathrin ^a   Friesen, Claudia ^a   Neumaier, Bernd ^a   Berrie, Eleanor ^b   Bird, Pru ^b   Hale, Geoffrey ^b   Blumstein, Norbert M ^a   Waldmann, Herman ^b   Bunjes, Donald ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti CD45; Biodistribution; Dosimetry; Radiation absorbed dose; Radioimmunotherapy

Indexed keywords

ANTILEUKEMIC AGENT; CD45 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY YAML 568; MONOCLONAL ANTIBODY YAML 568 IN 111 CONJUGATE; UNCLASSIFIED DRUG; YTTRIUM 90; MONOCLONAL ANTIBODY YAML568;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; ARTICLE; BLOOD SAMPLING; BONE MARROW; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; FEMALE; HUMAN; ISOTOPE LABELING; KIDNEY; LEUKOCYTE; LINEAR REGRESSION ANALYSIS; LIVER; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SPLEEN; URINALYSIS; AGED; ALLOTRANSPLANTATION; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; CHEMISTRY; METHODOLOGY; MIDDLE AGED; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33749052938     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Giles F, O'Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104:547-554.
2. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant. 2005;36:1021-1026.
3. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867-1871.
4. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
5. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl):115S-127S.
6. Jurcic JG. Immunotherapy for acute myeloid leukemia. Curr Oncol Rep. 2005;7:339-349.
7. Buchmann I, Meyer RG, Herr W, Helisch A, Bartenstein P. Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome: conceptual changes. Nuklearmedizin. 2005;44:107-117.
8. 213Bi-labeled antibody constructs for clinical use. J Nucl Med. 1999;40:1722-1727.
9. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935-1946.
10. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
11. 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45:129-137.
12. Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55(suppl):5908s- 5910s.
13. 131I labelled anti-CD45 antibody combined with cyclophosphamide and total body irradiation. Blood. 1995;85:1122-1131.
14. 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
15. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32:549-556.
16. 131I-Anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107:2184-2191.
17. Seitz U, Neumaier B, Glatting G, Kotzerke J, Bunjes D, Reske SN. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med. 1999;26:1265-1273.
18. 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med. 2000;41:531-537.
19. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98:565-572.
20. Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med. 2001;28:807-815.
21. 188Re-Labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma. 2002;43:2125-2131.
22. Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm. 2002;17:151-163.
23. Jurcic JG, Divgi CCR, McDevitt MR. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia [abstract]. Proc Am Soc Clin Oncol. 2000;19:24.
24. 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005;130:604-613.
25. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med. 2005;46(suppl):199S-204S.
26. Nourigat C, Badger CC, Bernstein ID. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst. 1990;82:47-50.
27. Hale G, Buckie C, Lovat P, Prospero T, Waldmann H. Epitope mapping of the human leucocyte common antigen by competitive binding and synergistic lysis. In: McMichael AJ, ed. Leucocyte Typing III: White Cell Differentiation Antigens. Oxford, U.K.: Oxford University Press; 1987:811-814.
28. Bindon CI, Hale G, Clark M, Waldmann H. Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen: synergy and interference in complement-mediated lysis. Transplantation. 1985;40:538-544.
29. 99mTc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2003;30:667-673.
30. Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol. 1985;134:3056-3061.
31. Wing MG, Waldmann H, Isaacs I, Compston DAS, Hale G. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther Immunol. 1995;2:183-190.
32. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement mediated lysis by monoclonal antibodies. Eur J Immunol. 1988;18:1507-1514.
33. Galfre G, Milstein C, Wright B. Rat x rat hybridomas and a monoclonal anti-Fd portion of mouse IgG. Nature. 1979;277:131-133.
34. Phillips J, Drumm A, Harrison P, et al. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. Cytotherapy. 2001;3:233-242.
35. Corson DT, Meares CF. Efficient multigram synthesis of the bifunctional chelating agent (S)-1-p-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid. Bioconjug Chem. 2000;11:292-299.
36. Glatting G, Landmann M, Kull T, et al. Internal radionuclide therapy: the UlmDos software for treatment planning. Med Phys. 2005;32:2399-2405.
37. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
38. 131I-labeled anti-myeloid antibody in normal dogs: effects of a "cold" antibody pretreatment dose on marrow localization. Exp Hematol. 1989;17:929-934.
39. Wong JY, Chu DZ, Yamauchi D, et al. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. J Nucl Med. 1998;39:2097-2104.
40. Nemecek ER, Hamlin DK, Fisher D, et al. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a non human primate model. Clin Cancer Res. 2005;11:787-794.